Cargando…

Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma

We conducted a comprehensive analysis to evaluate clinical utility of decarboxylation prothrombin combined with α-fetoprotein (AFP) for diagnosing primary hepatocellular carcinoma (HCC). Systematical searches were performed in PubMed, Web of Science, China National Knowledge Internet, and Wangfang d...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Jun, Li, Yanyan, Li, Zhanzhan, Li, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172421/
https://www.ncbi.nlm.nih.gov/pubmed/29717027
http://dx.doi.org/10.1042/BSR20180044
_version_ 1783360945328750592
author Fu, Jun
Li, Yanyan
Li, Zhanzhan
Li, Na
author_facet Fu, Jun
Li, Yanyan
Li, Zhanzhan
Li, Na
author_sort Fu, Jun
collection PubMed
description We conducted a comprehensive analysis to evaluate clinical utility of decarboxylation prothrombin combined with α-fetoprotein (AFP) for diagnosing primary hepatocellular carcinoma (HCC). Systematical searches were performed in PubMed, Web of Science, China National Knowledge Internet, and Wangfang databases. The bivariate random-effect model was used to calculate the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood, diagnostic odds ratio (DOR), and summary area under the curve (AUC). Fourteen studies were included in the meta-analysis. For decarboxylation prothrombin, the overall pooled parameters are as follows: sensitivity: 79% (95% confidence interval (CI): 74–84%), specificity: 91% (95%CI: 87–93%), PLR: 8.42 (95%CI: 5.79–12.23), negative likelihood ratio (NLR): 0.23 (95%CI: 0.17–0.30), DOR: 37.09 (95%CI: 21.37–64.36), summary AUC: 0.92 (95%CI: 0.89–0.94); for combined diagnostic, the overall pooled parameters were as follows: sensitivity: 91% (95%CI: 85–95%), specificity: 83% (95%CI: 74–89%), PLR: 5.26 (95%CI: 3.53–7.83), NLR: 0.11 (95%CI: 0.07–0.18), DOR: 47.14 (95%CI: 30.09–73.85), summary AUC: 0.94 (95%CI: 0.91–0.95). The serum decarboxylation prothrombin showed a relatively higher diagnostic specificity for primary HCC and decarboxylation prothrombin combined with AFP exhibited can improve sensitivity for HCC than any of the biomarkers alone.
format Online
Article
Text
id pubmed-6172421
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-61724212018-10-19 Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma Fu, Jun Li, Yanyan Li, Zhanzhan Li, Na Biosci Rep Research Articles We conducted a comprehensive analysis to evaluate clinical utility of decarboxylation prothrombin combined with α-fetoprotein (AFP) for diagnosing primary hepatocellular carcinoma (HCC). Systematical searches were performed in PubMed, Web of Science, China National Knowledge Internet, and Wangfang databases. The bivariate random-effect model was used to calculate the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood, diagnostic odds ratio (DOR), and summary area under the curve (AUC). Fourteen studies were included in the meta-analysis. For decarboxylation prothrombin, the overall pooled parameters are as follows: sensitivity: 79% (95% confidence interval (CI): 74–84%), specificity: 91% (95%CI: 87–93%), PLR: 8.42 (95%CI: 5.79–12.23), negative likelihood ratio (NLR): 0.23 (95%CI: 0.17–0.30), DOR: 37.09 (95%CI: 21.37–64.36), summary AUC: 0.92 (95%CI: 0.89–0.94); for combined diagnostic, the overall pooled parameters were as follows: sensitivity: 91% (95%CI: 85–95%), specificity: 83% (95%CI: 74–89%), PLR: 5.26 (95%CI: 3.53–7.83), NLR: 0.11 (95%CI: 0.07–0.18), DOR: 47.14 (95%CI: 30.09–73.85), summary AUC: 0.94 (95%CI: 0.91–0.95). The serum decarboxylation prothrombin showed a relatively higher diagnostic specificity for primary HCC and decarboxylation prothrombin combined with AFP exhibited can improve sensitivity for HCC than any of the biomarkers alone. Portland Press Ltd. 2018-10-05 /pmc/articles/PMC6172421/ /pubmed/29717027 http://dx.doi.org/10.1042/BSR20180044 Text en © 2018 The Author(s). http://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Articles
Fu, Jun
Li, Yanyan
Li, Zhanzhan
Li, Na
Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma
title Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma
title_full Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma
title_fullStr Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma
title_full_unstemmed Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma
title_short Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma
title_sort clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172421/
https://www.ncbi.nlm.nih.gov/pubmed/29717027
http://dx.doi.org/10.1042/BSR20180044
work_keys_str_mv AT fujun clinicalutilityofdecarboxylationprothrombincombinedwithafetoproteinfordiagnosingprimaryhepatocellularcarcinoma
AT liyanyan clinicalutilityofdecarboxylationprothrombincombinedwithafetoproteinfordiagnosingprimaryhepatocellularcarcinoma
AT lizhanzhan clinicalutilityofdecarboxylationprothrombincombinedwithafetoproteinfordiagnosingprimaryhepatocellularcarcinoma
AT lina clinicalutilityofdecarboxylationprothrombincombinedwithafetoproteinfordiagnosingprimaryhepatocellularcarcinoma